Fred Upton
Showing 1–3 of 3 transcripts.
- a16z17 min
a16z Podcast | Innovation and Regulation -- What Happens When Policy Lags Behind Technology?
Fred Upton, Greg Walden, Michael Copeland, Sonal
The House Energy and Commerce Committee, led by Chairman Fred Upton and Subcommittee Chair Greg Walden, is driving legislative and regulatory reforms to modernize telecommunications and accelerate medical innovation through the bipartisan 21st Century Cures Act. These initiatives prioritize deregulation and market forces to resolve legacy framework bottlenecks, while securing a projected $35 billion to $70 billion in spectrum auction revenue to fund public safety networks and NIH research. By streamlining FDA approval processes and establishing a $2 billion annual research funding stream, the committee aims to reverse the overseas shift in venture capital investment and ensure U.S. leadership in life-saving technologies.
- Milken Institute1h 26m
Public Health Summit Dinner March 2, 2016
Mike Milken, Tom Frieden, Rob Califf, Fred Upton, Nancy Pelosi, Francis Collins
This event featured key figures including Francis Collins, FDA Commissioner Rob Califf, and CDC Director Tom Frieden discussing critical public health challenges such as the implementation gap between knowledge and action, rising opioid overdose deaths, and the threat of a post-antibiotic era. The proceedings highlighted specific policy responses ranging from Mexico's successful food taxes and "health stops" to the U.S. House passing the 21st Century Cures Act and funding the Brain Initiative, alongside clinical breakthroughs in treating depression and heart failure. To address these systemic issues, officials urged for robust funding, the adoption of global "find, stop, prevent" strategies, and a massive volunteer effort for the Precision Medicine Initiative to accelerate biomedical discovery.
- Milken Institute55 min
The Promise of Public Health
Mike Klowden, Richard Besser, Nancy Brown, Thomas Farley, Joseph Jimenez, Fred Upton
The Milken Institute's inaugural Public Health Summit convened key industry and government leaders, including Novartis CEO Joe Jimenez, CDC Director Tom Frieden, and Congressman Fred Upton, to advocate for elevating disease prevention alongside medical cures. Participants analyzed critical strategies such as conditional reimbursement models, real-time data utilization, and the "21st Century Cures Act" to address looming challenges posed by an aging global population and stagnant biotech venture capital. The consensus emphasized that sustainable health outcomes require shifting from volume-based treatment to outcome-based policies that integrate genomics, behavioral interventions, and bipartisan legislative support to bridge significant disparities in US public health metrics.